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ABSTRACT 1 
Aims: To examine the distribution of liver fat (LFAT) in non-diabetic subjects 2 
and test whether the fat in the right as compared to the left lobe correlates 3 
better with components of the metabolic syndrome or not. 4 
Methods: In this cross sectional study, we determined LFAT by 1H-MRS in the 5 
right lobe (LFAT%MRS), and by MRI (LFAT%MRI) in four regions of interest 6 
(ROIs1-4, two in the right and two in the left lobe) in 97 non-diabetic subjects 7 
(age range 22-74yrs, BMI 18-41 kg/m2) and compared the accuracy of LFATMRI 8 
in the different ROIs in diagnosing non-alcoholic fatty liver disease (NAFLD) 9 
using areas under the receiver operator characteristic (AUROC) curves. 10 
Results: 38% of the subjects had NAFLD (LFAT%MRS). LFAT%MRI was 11 
significantly higher in the right (5.7±0.5%) than the left (5.1±0.4%) lobe 12 
(p<0.02).The AUROC for LFAT%MRI in the right lobe for diagnosing NAFLD 13 
was significantly better than that in the left lobe. The relationships between 14 
several metabolic parameters and LFAT%MRI in the left lobe were significantly 15 
worse than those for LFAT%MRS while there was no difference between 16 
LFAT%MRS and right lobe ROIs.  17 
Conclusions: Liver right lobe contains more fat and correlates better with 18 
components of the metabolic syndrome than the left in non-diabetic subjects.  19 
 20 
Key words:  metabolic syndrome, insulin, obesity  21 
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1. Introduction 1 
Studies performed in dogs over 100 years ago showed that blood flow from the 2 
splenic vein streamlined to the left lobe of the liver, while blood from the 3 
superior mesenteric vein was directed to the right lobe[1, 2]. Similarly, studies 4 
in humans have shown that blood from the superior mesenteric vein, which 5 
drains the right colon, ileum and jejunum, is directed to the right lobe while 6 
blood from the spleen and left colon drain to the left lobe[3]. In obese subjects, 7 
the rate of visceral lipolysis is increased compared to non-obese subjects and 8 
can account for up to 50% of free fatty acids (FFA) delivery to the liver[4]. Many 9 
obese subjects accumulate fat in the liver due to non-alcoholic causes (NAFLD) 10 
and therefore possibly an increased flux of FFA from visceral fat to the superior 11 
mesenteric vein. Studies using Doppler ultrasonography in healthy volunteers 12 
have shown that in response to a meal, intrahepatic portal vein blood flow 13 
increases more in the right than the left lobe [5]. FFA delivery from both the 14 
meal and from visceral lipolysis might preferentially increase liver fat content 15 
more in the right than the left lobe. Metabolic consequences of hepatic insulin 16 
resistance in NAFLD such as hyperinsulinemia and hypertriglyceridemia could 17 
therefore also be better correlated with fat in the right than the left lobe.       18 
 19 
Few data are available examining fat distribution in the human liver. In an 20 
autopsy study, Merat et al [6] analyzed three different parts of the liver (2×2×2 21 
cm each) and found steatosis to be unevenly distributed (kappa = 0.64). 22 
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Larson et al [7] and Merriman et al [8] took liver biopsies from the right and left 1 
lobes of morbidly obese patients and found low variability for steatosis 2 
between right and left lobes. However, multiple liver biopsies can not be used 3 
to assess heterogeneity of liver fat because of risks of bleeding.  4 
 5 
Magnetic resonance imaging (MRI) methods enable accurate assessment of 6 
liver steatosis[9, 10].Until now, only one study has been published where 7 
heterogeneity of liver fat was analyzed in hospitalized patients with type 2 8 
diabetes, who were using oral hypoglycaemic agents or insulin, and the right 9 
lobe was found to contain more fat than the left lobe[11]. However, the 10 
pathways leading to NAFLD may differ between type 2 diabetic patients and 11 
non-diabetic subjects[12], and the drugs, especially insulin and glitazones 12 
could affect the routes which regulate intrahepatic fat content[13],[14]. 13 
Regional variation in liver fat content in non-diabetic subjects has not been 14 
examined.  15 
 16 
The liver is the source of glucose and (VLDL) triglycerides after an overnight 17 
fast, two of the key components of the metabolic syndrome. The liver, once 18 
fatty, becomes resistant to the normal actions of insulin to inhibit the production 19 
of glucose and VLDL[15]. This leads to hyperglycemia and stimulation of 20 
insulin secretion as well as hypertriglyceridemia[16]. All components of the 21 
metabolic syndrome are significantly correlated with liver fat content [15]. 22 
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However, if there is, as discussed above, more fat in the right than the left lobe, 1 
the former might be better correlated with features of insulin resistance than 2 
the latter. Indeed, identification of the region, which best correlates with 3 
features of insulin resistance, could be considered as the region which 4 
physiologically defines the most relevant area of fat accumulation in the liver, 5 
and provides the area which enables the most accurate diagnosis of NAFLD.  6 
 7 
In the present study, we hypothesized that the right lobe of the human liver 8 
would contain more fat than the left lobe in non-diabetic subjects, and that fat 9 
in the right as compared to the left lobe might correlate better with components 10 
of the metabolic syndrome. To this end, we quantified liver fat by MRI in 4 11 
different regions of interest (ROIs) in 97 non-diabetic subjects, and also 12 
measured liver fat by proton magnetic resonance spectroscopy (1H-MRS), the 13 
golden standard for measurement of liver fat content. 14 
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2. Methods 1 
2.1. Subjects 2 
We analyzed data from all non-diabetic subjects studied since August 2007 3 
when we added an in-phase (IP) and out-of-phase (OP) imaging sequence to 4 
our MRI protocol to enable monitoring of spatial distribution of fat in the liver. 5 
This sequence covers the whole liver and allows to quantitate the intensity of 6 
the liver. The group comprised of 97 subjects (56women, 41men), who met the 7 
following inclusion criteria: i) age 20 to 75 years, ii) no known acute or chronic 8 
disease other than obesity, hypertension or NAFLD. iii) no evidence of 9 
advanced fibrosis as determined using the NAFLD fibrosis score[17]. 10 
Exclusion criteria included i) diabetes , ii) autoimmune liver disease (past 11 
medical history); iii) viral liver disease (positive for HBsAg or HCVAb) , iv) 12 
drug-induced liver disease (past medical and drug use history), v) excessive 13 
use of alcohol (more than 20g/day for men, more than 10g/day in women[18]), 14 
vi) pregnancy or lactation. All protocols were in accordance with the Helsinki 15 
Declaration of 1975 and approved by the ethics committee of the Helsinki 16 
University Central Hospital, and each subject provided written informed 17 
consent. 18 
 19 
Eligible subjects were studied after an overnight fast. At this visit, body weight 20 
and height, waist and hip circumferences were measured, % body fat and 21 
blood pressure were recorded, and blood samples were taken for 22 
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measurement of biochemical parameters as detailed below. On a second 1 
occasion, 1H-MRS and MRI studies were performed to quantitate liver fat (vide 2 
infra).  3 
 4 
2.2. % Liver fat (1H-MRS) 5 
Localised single voxel (2×2×2 cm3) proton spectra were acquired using a 1.5-T 6 
whole-body system (Siemens Magnetom Avanto, Erlangen, Germany), which 7 
consisted of a combination of whole-body and loop surface coils for 8 
radiofrequency transmitting and signal receiving. T1- and T2-weighted 9 
high-resolution MR images were used for localisation of the voxel of interest 10 
within the right lobe of the liver. 1H-MRS measurements of the liver fat were 11 
performed in the middle of the right lobe at a location that was individually 12 
determined for each subject by a single operator; vascular structures and 13 
subcutaneous fat tissue were avoided when selecting the voxel. Single voxel 14 
spectra were recorded using the point resolved spectroscopy (PRESS), with 15 
an echo time of 30 msec, a repetition time of 3000 msec, 1024 data points 16 
over 1000 kHz spectral width with 16 averages. A short echo time and long 17 
repetition time were chosen to ensure a fully relaxed water signal, which was 18 
used as an internal standard. Chemical shifts were measured relative to water 19 
at 4.70 ppm. The methylene signal, which represents intracellular triglyceride, 20 
was measured at 1.3 ppm. Signal intensities were quantified by using a jMRUI 21 
v3.0 analysis program [19] with an advanced method for accurate, robust and 22 
9 
 
efficient spectral fitting (AMARES)[20]. Signal intensities were corrected for T2 1 
relaxation as previously described[21]. Spectroscopic intracellular triglyceride 2 
content (LFAT) was expressed as a ratio of the area under the methylene peak 3 
to that under the methylene and water peaks. LFAT% was converted from 4 
signal ratios to volume fractions by applying the method validated by Longo et 5 
al [22] and using experimentally determined values by Szczepaniak et al. 6 
[23](x 100 = % liver fat). This measurement has been validated against 7 
histologically determined lipid content [24] and against estimates of fatty 8 
degeneration or infiltration by X-ray computer-assisted tomography by us [25] 9 
and others[26]. All spectra were analysed by a physicist who was unaware of 10 
any of the clinical data. The reproducibility of repeated measurements of LFAT 11 
in non-diabetic subjects studied on two occasions in our laboratory is 11%. 12 
NAFLD was defined as in the population-based Dallas Heart Study, as a 13 
LFAT%> 5.55%[27]. 14 
 15 
2.3. Liver fat fraction (MRI) 16 
A body coil was used to obtain coronal scout images of the upper abdomen. A 17 
stack of transaxial IP and OP T1-weighted dual-echo fast spoiled-gradient 18 
recalled images were obtained in two breath holds using following imaging 19 
parameters: 103 msec repetition time, 2.12 msec (OP)/4.8 msec (IP) echo time, 20 
80° flip angle, 24 slices (x2), 1 cm slice thickness, 512 x 448 matrix and 5 dm x 21 
4.37 dm field of view, the same matrix and field was used for all patients. 22 
10 
 
Trans-axial abdominal scans encompassing the entire liver were acquired in 1 
two breath-holds using the magnet mentioned above. Each 2D slice was 2 
displayed on the video screen. Using the Image J 1.46r software to analyze the 3 
intensity of the liver, four ROIs (1-2 cm in diameter) were obtained in the liver 4 
above the portal vein (two in the right lobe and two in the left lobe, Fig.1). ROIs 5 
1-4were located in liver segments II, IV, VIII, VII, respectively. The standard 6 
deviation of the signal intensity measure ements within each ROI was kept to 7 
less than 10%.The ROIs included areas of parenchyma that did not contain 8 
vessels or artifacts, and the ROIs were in corresponding locations in the paired 9 
IP and OP MR images. The signal intensity of the spleen was measured as the 10 
mean intensity from the three 1 to 2 cm ROIs (Fig.1). LFATFrMRI was quantified 11 
on T1-weighted dual-echo gradient-echo MR images as the percentage of 12 
relative signal intensity loss of the liver on OP images, with the following 13 
formula: (SIin- SIout) / SIin× 100, where SI is the mean liver signal intensity 14 
divided by the mean spleen signal intensity, SIin is IP signal intensity, and SIout 15 
is OP signal intensity [10]. LFATFrMRI was converted to 1H-MRS % units(% liver 16 
fat by MRI, LFAT%MRI) using the equation relating MRI and 1H-MRS 17 
measurements(see results). 18 
 19 
2.4. Intra-abdominal fat and subcutaneous fat (MRI) 20 
A series 16 of T1-weighted axial images with selective fat excitation were 21 
acquired from a region extending from 8 cm above to 8 cm below the L4/5 22 
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lumbar intervertebral disks (16 slices, field of view 438×500 mm2, slice 1 
thickness 1cm, breath-hold repetition time 91 msec, echo time 5.24 msec). 2 
Intra-abdominal and subcutaneous fat areas for each slice were determined 3 
using a region growing method in SliceOmatic v4.3 image analysis program 4 
(Tomovision, Montreal, Canada). The areas were multiplied by the slice 5 
thickness and the results were expressed as total volumes of Intra-abdominal 6 
and subcutaneous adipose tissues[25]. 7 
 8 
2.5. Other measurements and analytical procedures 9 
Waist circumference was measured midway between the spinailiaca superior 10 
and the lower rib margin, and hip circumference at the level of the greater 11 
trochanters [28]. Body weight was recorded to the nearest 0.1 kg using a 12 
calibrated weighting scale (Soehnle, Monilaite-Dayton, Finland) with subjects 13 
barefoot and wearing light indoor clothing. Body height was recorded to the 14 
nearest 0.5 cm using a ruler attached to the scale. % body fat was determined 15 
by bioimpedance plethysmography as previously described [29]. 16 
 17 
Blood pressure was measured in the sitting position after 10 to 15 minutes of 18 
rest using a random-zero sphygmomanometer (Erka, Germany). Fasting 19 
plasma glucose (FPG) concentrations were measured in duplicate using the 20 
glucose oxidase method using Beckman Glucose Analyzer II (Beckman 21 
Instruments, Fullerton, CA)[30]. Fasting serum (fS) free insulin concentrations 22 
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were measured with the Auto-DELFIA kit (Wallac, Turku, Finland). 1 
Glycosylated hemoglobin A1c (HbA1c) was measured by high performance 2 
liquid chromatography using the fully automated Glycosylated Haemoglobin 3 
Analyzer System (BioRad, Richmond, CA)[31]. Serum (S) total cholesterol, 4 
high density lipoprotein (HDL) cholesterol and triglyceride concentrations were 5 
measured with the enzymatic kits from Roche Diagnostics using an 6 
auto-analyser (Roche Diagnostics Hitachi, Hitachi Ltd., Tokyo, Japan). The 7 
concentrations of low density lipoprotein (LDL) cholesterol were calculated 8 
using the Friedewald formula[32]. Serum albumin, blood counts, alanine 9 
aminotransferase (ALT), aspartate aminotransferase (AST) and 10 
gamma-glutamyltransferase (GGT) activities were determined as 11 
recommended by the European Committee for Clinical Laboratory Standards. 12 
The NAFLD fibrosis score was calculated as described by Angulo et al [17] 13 
and as recommended by the American College of Gastroenterology[33]. 14 
Serum hepatitis B virus surface antigen (HBsAg) and hepatitis C virus antibody 15 
(HCV-Ab) were tested by the Enhanced Electrochemiluminescence method. 16 
 17 
Homeostasis model assessment-insulin resistance (HOMA-IR) was calculated 18 
as described by Matthews et al [34]. 19 
 20 
2.6. Statistical analyses 21 
13 
 
Normal distribution of data was analyzed using the Kolmogorov-Smirnov test. 1 
Non-normally distributed data were used after logarithmic (base 10) 2 
transformation. Normally distributed data are shown as mean ± SE, whereas 3 
non-normally distributed data are shown as median followed by the 25% and 4 
75% percentiles. The unpaired Student s t-test and the Mann-Whitney test 5 
were used to compare mean values of normally and non-normally distributed 6 
data. Pearson’s correlation coefficient was calculated for normally and 7 
Spearman’s rank correlation coefficient for non-normally distributed data. Lin’s 8 
concordance coefficient, which combines measurements of precision and 9 
accuracy, was computed to determine whether the observed data deviate 10 
significantly from the line of perfect agreement[35]. Multiple linear regression 11 
analysis was performed to set an equation to get the LFAT%MRI from 12 
LFATFrMRI using LFAT%MRS as reference standard and test which part of  13 
LFAT%MRI was the independent predictor of LFAT%MRS. Correlation 14 
coefficients were compared using the Hotelling-Williams test by R 2.13.1 15 
statistical package(R software, R Foundation for Statistical Computing, Vienna, 16 
Austria). Receiver operating characteristic (ROC) curves were set up by SPSS 17 
20.0 for Windows (SPSS, Chicago, IL) and compared using the Medcalc 18 
12.7.1.0 (MedCalc Software, Mariakerke, Belgium). Values of area under 19 
receiver operating characteristic (AUROC)equalling 1 represent a perfect test; 20 
between 0.9 and 1 were considered as excellent; between 0.8 and 0.9 good; 21 
between 0.7 and 0.8 fare; between 0.6 and 0.7 poor; and0.5 a worthless test. 22 
14 
 
Other calculations were made using SPSS 20.0 for Windows and GraphPad 1 
Prism version 5.00 for Windows (GraphPad Software, San Diego, CA). A 2 
p-value of less than 0.05 was considered statistically significant.3 
15 
 
3. Results 1 
3.1. Characteristics of the study subjects 2 
Anthropometric and biochemical characteristics of the subjects are 3 
summarized in Table 1. 38% of the subjects had NAFLD as measured by 4 
LFAT%MRS. None of the subjects had evidence of fibrosis (NAFLD fibrosis 5 
score< 0.676 [17]). The LFAT%MRS averaged 5.8±0.6% (1.9±0.2% for 6 
non-NAFLD, 12.0±0.7% for NAFLD, p<0.001).  7 
 8 
3.2. Regional variation in liver fat 9 
The equation relating LFAT%MRS (right lobe) and LFATFrMRI (right lobe) was as 10 
follows: LFAT%MRS= (2.837 ± 0.374) + (0.198 ± 0.013) × LFATFrMRI (r=0.837, 11 
p<0.001, Fig. 2). LFAT%MRI in ROIs 1, 2, 3 and 4 averaged: 4.8±0.5%, 12 
5.5±0.5%, 5.8±0.5% and 5.7±0.5%. The LFAT%MRI was significantly lower in 13 
ROI 1 than in ROI 2 (p<0.02), ROI 3 (p<0.001) and ROI 4 (p<0.02, Fig.3). 14 
LFAT%MRI was significantly higher in the right (5.7±0.5%) than the left 15 
(5.1±0.4%) lobe (p<0.02, Fig.3). 16 
 17 
The correlation coefficients (Pearson) between LFAT%MRS and LFATFrMRI in 18 
ROIs were: r=0.738, p<0.001 for ROI 1, r=0.785, p<0.001 for ROI 2, r=0.825, 19 
p<0.001 for ROI 3, r=0.828, p<0.001 for ROI 4; r=0.837, p<0.001 for the right 20 
lobe and r=0.781, p<0.001 for the left lobe. Lin’s concordance coefficients 21 
between LFAT%MRS and LFAT%MRI in ROIs were: rho(c)=0.704, p<0.001 for 22 
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ROI 1, rho(c)=0.763, p<0.001 for ROI 2, rho(c)=0.808, p<0.001 for ROI 3, and 1 
rho(c)=0.820, p<0.001 for ROI 4, rho(c)=0.824, p<0.001 for the right lobe, 2 
rho(c)=0.74, p<0.001 for the left lobe. 3 
 4 
Multiple linear regression analysis showed LFAT%MRI in the right but not the 5 
left lobe was an independent predictor of LFAT%MRS (β=0.160, p<0.001). 6 
 7 
We analyzed ROC curves to determine how use of different ROIs influence the 8 
diagnosis of NAFLD. LFAT%MRI in ROI 3 showed excellent accuracy in 9 
diagnosing NAFLD (AUROC = 0.936±0.023, p< 0.001, sensitivity 94.6%, 10 
specificity 83.3%). The AUROC for ROI 1 was good (AUROC = 0.879±0.034, 11 
p< 0.001, sensitivity 70.3%, specificity 90.0%) but significantly lower than that 12 
of AUROC for ROI 3 (p<0.02; Table 2). Likewise, the AUROC was significantly 13 
higher using LFAT%MRI in the right (AUROC = 0.934±0.025,p< 0.001, 14 
sensitivity 86.5%, specificity 90.0%) than in the left lobe 15 
(AUROC = 0.894±0.032,p< 0.001, sensitivity 73.0%, specificity 91.7%) lobe 16 
(p<0.05, Table 2, Fig. 4). 17 
 18 
3.3. Metabolic parameters and liver fat in different ROIs 19 
The relationships between metabolic parameters and LFAT%MRS and 20 
LFAT%MRI in the different ROIs are shown in Table 3. The correlation 21 
coefficients between BMI, waist and hip circumference, body fat, 22 
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intra-abdominal and subcutaneous fat, S-AST, S-ALT and LFAT%MRS were 1 
significantly higher than those between these metabolic features and 2 
LFAT%MRI in ROI 1 (Fig. 5, Table 3). The correlation coefficient between 3 
HOMA-IR, S-AST,S-ALTand LFAT% MRI in ROI 2 was significantly lower than 4 
those between LFAT%MRS and these metabolic features (Fig. 5, Table 3). The 5 
correlation coefficients between the metabolic parameters and LFAT%MRI in 6 
ROIs 3 and 4 did not differ from those relating the respective parameters and 7 
LFAT%MRS (Fig. 5, Table 3).8 
18 
 
4. Discussion 1 
In the present study of 97 non-diabetic subjects, we found the right lobe of the 2 
liver to contain significantly more fat than the left lobe. Measurement of liver fat 3 
in the right lobe perhaps provided a significantly more accurate diagnosis of 4 
NAFLD than that in the left lobe. Since liver fat was not homogenously 5 
distributed, we examined, which region in the liver was most closely 6 
associated with metabolic abnormalities associated with NAFLD. The 7 
correlation coefficients for measures of obesity, liver enzymes and HOMA-IR 8 
were best associated with fat in the right lobe of the liver. The right lobe could 9 
therefore be recommended as the location for quantification of liver fat in 10 
diagnosing NAFLD.  11 
 12 
Compared to 1H-MRS, MRI is available on most MR units and can be 13 
performed easily in routine examinations [36].Previous studies have shown 14 
that MRI-based measurements of the liver fat are closely correlated with those 15 
obtained by 1H-MRS [9, 37]. These studies included patients with type 2 16 
diabetes (n=33) and those with a fatty liver (n=12), and found the correlation 17 
coefficient between MRI and 1H-MRS methods to be 0.959 [9] and 0.950 [37]. 18 
The correlation coefficient found in the present study in 97 subjects (0.837) is 19 
in line with these data. 20 
 21 
Distribution of liver fat has been analysed using MRI or MRS in only one 22 
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study[11]. In the study of Captan et al in hospitalized type 2 diabetic patients, 1 
liver fat averaged 8.9% in the right and 7.7% in the left lobe (p<0.001). The 2 
present data in non-diabetic subjects showed a similar difference in the fat 3 
content of the liver lobes as Captan et al[11].  4 
 5 
The present study does not provide mechanistic insights as to why liver fat 6 
content is significantly higher in the right than the left lobe. The most probable 7 
explanation is provided by previous data showing that portal blood flow is 8 
streamline rather than turbulent. Portal blood flow conveyed via the superior 9 
mesenteric vein drains visceral fat and supplies the right lobe of the liver while 10 
blood from the spleen flows into the left lobe[1, 2]. Fat does not accumulate in 11 
the spleen in obesity[38, 39]. In keeping with these data on blood flow and on 12 
the increased visceral lipolysis in obesity[4], we found waist circumference and 13 
visceral fat to correlate better with fat in the right than the left lobe. Dauzat et al 14 
measured the hemodynamic effects of a meal on the splanchnic and hepatic 15 
circulation in 30 healthy volunteers using Doppler ultrasonography[5]. 16 
Intrahepatic portal blood flow was shown to increase significantly more in the 17 
right than the left lobe [5]. Thus, the right lobe may receive more substrates for 18 
hepatic lipogenesis such as fatty acids, glucose and amino acid also 19 
postprandially. Direct measurement of blood flow distribution in the liver of 20 
patients with NAFLD combined with quantification of the contribution of 21 
different pathways (lipolysis, de novo lipogenesis, the spillover pathways, 22 
20 
 
uptake of chylomicron remnants postprandially) would be needed to provide 1 
mechanistic insights for the present data. 2 
 3 
The present data are to our knowledge the first to relate metabolic features of 4 
NAFLD to fat content of different regions of the liver. Given the heterogeneous 5 
distribution of liver fat, such analysis is of interest as it helps to identify the 6 
region of the liver, which should be used for diagnosis of NAFLD. We found the 7 
correlation coefficients between LFAT%MRI in ROI3 and ROI4 and measures of 8 
both subcutaneous and visceral obesity to be as good as those between these 9 
measures and LFAT%MRS. The correlation coefficient between LFAT%MRI in 10 
ROI1 was worse than that between the measures of obesity and LFAT%MRS. 11 
These data suggest that obesity increases liver fat especially in the right lobe 12 
of the liver. Liver enzymes, a simple but not ideal marker of NAFLD and 13 
non-alcoholic steatohepatitis (NASH)[40] ,were also better correlated with liver 14 
fat in the right lobe. Finally, HOMA-IR, a product of fasting insulin and glucose, 15 
was significantly worse correlated with LFAT%MRI in ROI 2 but not the other 16 
ROIs than with LFAT%MRS. These data suggest that fat accumulates in the 17 
right region of the liver and that this may correlate better with insulin resistance 18 
and metabolic abnormalities than the left .  19 
 20 
One limitation of our study was only addressed to evaluate the relative 21 
distribution of liver fat into the right and the left lobe and its association with 22 
21 
 
metabolic abnormalities, but not addressed to explore the relationship between 1 
the liver fat distribution and the severity of liver damage. Accordingly, no 2 
insights about this relationship should be provided. Another shortcoming was 3 
that we did not offer much mechanism as to heterogeneity of liver fat that 4 
should be further studied in the future.  5 
 6 
5. Conclusion 7 
In conclusion, liver fat is heterogeneously distributed in non-diabetic subjects, 8 
right lobe containing more fat than the left. When measured by MRI as in the 9 
present study, quantification of fat in the right as compared to the left lobe 10 
perhaps allows a more accurate diagnosis of NAFLD (Fig. 4). Metabolic 11 
abnormalities including obesity, liver enzymes and insulin resistance are also 12 
closer associated with fat in the right than in the left lobe (Table 3, Fig. 5). 13 
Quantification of liver fat in the right lobe may become of increasing clinical 14 
interest by ultrasound techniques or in conjunction with abdominal MRI 15 
performed for other indications. The study results are preliminary and need to 16 
be reproduced in a larger sample size and validated. 17 
22 
 
Acknowledgements 1 
We gratefully acknowledge Anne Salo, Katja Sohlo and Mia Urjansson 2 
(Helsinki University Central Hospital, Department of Medicine) as well as Pentti 3 
Pölönen (Helsinki University Central Hospital, Department of Radiology) for 4 
skilful technical assistance. 5 
 6 
Authors’ contributions are as follows – HB: research conduction, statistical 7 
analyses and interpretation of the data, drafting and critical revision of the 8 
manuscript; AH: research design and conduction; YZ: statistical analyses; NL: 9 
research design and conduction, critical revision of the manuscript; HYJ: 10 
research design and conduction, analysis and interpretation of the data, 11 
drafting and critical revision of the manuscript, study supervision. 12 
 13 
None of the authors had a conflict of interest. 14 
 15 
Financial support: None 16 
23 
 
REFERENCES 
(1) Serege H. Contribution a l'etude de la circulation du sang porte dans le foie et des localizations 
lobaires hepatiques. Journal de Medecine de Bordeaux 1901;31:271-5,91-95,312-4. 
(2) Bartlett F, Corper H, Long E. The independence of the lobes of the liver. Amer I Physiol 
1914;35:36-50. 
(3) Gates GF, Dore EK. Streamline flow in the human portal vein. J Nucl Med. 1973;14:79-83. 
(4) Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest. 
2004;113:1582-8. 
(5) Dauzat M, Lafortune M, Patriquin H, et al. Meal induced changes in hepatic and splanchnic 
circulation: a noninvasive Doppler study in normal humans. Eur J Appl Physiol Occup Physiol. 
1994;68:373-80. 
(6) Merat S, Sotoudehmanesh R, Nouraie M, et al. Sampling error in histopathology findings of 
nonalcoholic fatty liver disease: a post mortem liver histology study. Arch Iran Med. 2012;15:418-21. 
(7) Larson SP, Bowers SP, Palekar NA, et al. Histopathologic variability between the right and left lobes 
of the liver in morbidly obese patients undergoing Roux-en-Y bypass. Clin Gastroenterol Hepatol. 
2007;5:1329-32. 
(8) Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese 
patients with suspected nonalcoholic fatty liver disease. Hepatology. 2006;44:874-80. 
(9) Borra RJ, Salo S, Dean K, et al. Nonalcoholic fatty liver disease: rapid evaluation of liver fat content 
with in-phase and out-of-phase MR imaging. Radiology. 2009;250:130-6. 
(10) Qayyum A, Goh JS, Kakar S, et al. Accuracy of liver fat quantification at MR imaging: comparison 
of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. 
Radiology. 2005;237:507-11. 
(11) Capitan V, Petit JM, Aho S, et al. Macroscopic heterogeneity of liver fat: an MR-based study in 
type-2 diabetic patients. Eur Radiol. 2012;22:2161-8. 
(12) Kotronen A, Juurinen L, Hakkarainen A, et al. Liver fat is increased in type 2 diabetic patients and 
underestimated by serum alanine aminotransferase compared with equally obese nondiabetic 
subjects. Diabetes Care. 2008;31:165-9. 
(13) Juurinen L, Tiikkainen M, Hakkinen AM, et al. Effects of insulin therapy on liver fat content and 
hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 
2007;292:E829-35. 
(14) Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-18. 
(15) Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. 
Arterioscler Thromb Vasc Biol. 2008;28:27-38. 
(16) Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 
activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human 
fatty liver. Diabetes. 2009;58:203-8. 
(17) Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that 
identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54. 
(18) Bhala N, Usherwood T, George J. Non-alcoholic fatty liver disease. BMJ. 2009;339:b2474. 
(19) Naressi A, Couturier C, Castang I, et al. Java-based graphical user interface for MRUI, a software 
package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol 
Med. 2001;31:269-86. 
24 
 
(20) Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient 
quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35-43. 
(21) Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and 
liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865-72. 
(22) Longo R, Pollesello P, Ricci C, et al. Proton MR spectroscopy in quantitative in vivo determination 
of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5:281-5. 
(23) Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H 
spectroscopy: validation in vivo. Am J Physiol. 1999;276:E977-89. 
(24) Thomsen C, Becker U, Winkler K, et al. Quantification of liver fat using magnetic resonance 
spectroscopy. Magn Reson Imaging. 1994;12:487-95. 
(25) Ryysy L, Hakkinen AM, Goto T, et al. Hepatic fat content and insulin action on free fatty acids and 
glucose metabolism rather than insulin absorption are associated with insulin requirements during 
insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749-58. 
(26) Lukaski HC, Johnson PE, Bolonchuk WW, et al. Assessment of fat-free mass using bioelectrical 
impedance measurements of the human body. Am J Clin Nutr. 1985;41:810-7. 
(27) Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure 
hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol 
Endocrinol Metab. 2005;288:E462-8. 
(28) Marti B, Tuomilehto J, Salomaa V, et al. Body fat distribution in the Finnish population: 
environmental determinants and predictive power for cardiovascular risk factor levels. J Epidemiol 
Community Health. 1991;45:131-7. 
(29) Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin 
Endocrinol Metab. 2007;92:3490-7. 
(30) Kadish AL, Sternberg J. A new and rapid method for the determination of glucose by 
measurement of rate of oxygen consumption. Clin Chem 1968;14:116-31. 
(31) Stenman UH, Pesonen K, Ylinen K, et al. Rapid chromatographic quantitation of glycosylated 
haemoglobins. J Chromatogr. 1984;297:327-32. 
(32) Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density 
lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 
1972;18:499-502. 
(33) Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty 
liver disease: practice guideline by the American Gastroenterological Association, American 
Association for the Study of Liver Diseases, and American College of Gastroenterology. 
Gastroenterology. 2012;142:1592-609. 
(34) Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance 
and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 
1985;28:412-9. 
(35) Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 
1989;45:255-68. 
(36) Springer F, Machann J, Claussen CD, et al. Liver fat content determined by magnetic resonance 
imaging and spectroscopy. World J Gastroenterol. 2010;16:1560-6. 
(37) Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for 
monitoring liver steatosis. J Magn Reson Imaging. 2008;28:937-45. 
(38) Piekarski J, Goldberg HI, Royal SA, et al. Difference between liver and spleen CT numbers in the 
25 
 
normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 
1980;137:727-9. 
(39) Nomura F, Ohnishi K, Ochiai T, et al. Obesity-related nonalcoholic fatty liver: CT features and 
follow-up studies after low-calorie diet. Radiology. 1987;162:845-7. 
(40) Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of 
nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-9. 
 
 
  
26 
 
27 
 
Table 1. Anthropometric and biochemical characteristics of the subjects. 
 Total 
(n=97)  
Non-NAFLD 
(n=60) 
NAFLD 
(n=37) 
Age (year)  51±1  49±2 54±2* 
Weight (kg)  83.6±1.8  77.9±2.0 92.2±2.9*** 
Body mass index (kg/m2)  28.3±0.5  26.6±0.6 31.0±0.8*** 
Waist circumference (cm) 94.9±1.6 89.9±1.9 102.7±2.2*** 
Hip circumference (cm) 104.7±1.1 101.3±1.2 110.1±1.8*** 
Waist-to-hip-ratio 0.90±0.01 0.88±0.01 0.93±0.01** 
Fasting plasma glucose 
(mmol/l) 
5.4±0.1  5.2±0.1  5.8±0.1*** 
fS-Insulin (mU/l) 6.1 (3.5-12.5)  4.6 (2.7-7.1)  12.0 (6.7-14.7)*** 
HOMA-IR  1.42 (0.84-3.09)  0.98 (0.60-1.70)  2.87 (1.68-3.74)*** 
fS-Triglycerides (mmol/l) 1.10 (0.74-1.57)  0.89 (0.70-1.29)  1.36 (0.93-1.86)** 
fS-HDL cholesterol (mmol/l) 1.44±0.04  1.57±0.06 1.26±0.05** 
fS-LDL cholesterol (mmol/l) 3.07±0.08  3.07±0.10 3.06±0.15 
S-ALT (U/L) 29 (22-44) 24 (17-32) 45 (35-66) 
S-AST (U/L) 30 (25-35) 26 (23-31) 35 (30-43) 
S-GGT (U/L) 24 (16-44) 19 (13-28) 36 (24-60) 
NAFLD fibrosis score -2.19±1.31 -2.36±1.17 -1.98±1.47 
NAFLD fibrosis score%† 0 0 0 
Abbreviations: NAFLD, non-alcoholic fatty liver disease; fS, fasting serum; HOMA-IR, 
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homeostasis model assessment-insulin resistance; S, serum; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; GGT gamma-glutamyltransferase; HDL, high density 
lipoprotein; LDL low density lipoprotein. Data are shown as mean ± SE or median (25% 
percentile, 75% percentile). *p<0.05, **p<0.02, ***p<0.001 for vs. non-NAFLD. †Patients with 
advanced fibrosis (NAFLD fibrosis score＞0.676). 
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Table 2. ROC curves to diagnose the NAFLD using LFAT%MRI in different ROIs  
 
AUROC SE p value for AUROC Sensitivity % Specificity % PPV % NPV % Youden index 
ROI 1 0.879 0.034 <0.001 70.3 90.0 81.3 83.0 0.603 
ROI 2 0.894 0.032 <0.001 83.8 78.3 70.5 88.7 0.621 
ROI 3 0.936**†† 0.023 <0.001 94.6 83.3 77.8 96.2 0.779 
ROI 4 0.930 0.029 <0.001 89.2 90.0 84.6 93.1 0.792 
Right lobe 0.934*†§ 0.025 <0.001 86.5 90.0 84.2 91.5 0.765 
Left lobe 0.894‡‡ 0.032 <0.001 73.0 91.7 84.4 84.6 0.647 
Abbreviations: ROC, receiver operating characteristic; NAFLD, non-alcoholic fatty liver disease; ROI, region of interest; 
AUROC, area under the receiver operating characteristic; PPV, positive predictive value; NPV, negative predictive value. 
*p<0.05, **p<0.02 for vs. ROI 1; †p<0.05, ††p<0.02 for vs. ROI 2; ‡‡p<0.02 for vs. ROI 3; §p<0.05 for vs. left lobe. 
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Table 3. Correlation coefficients between metabolic parameters and LFAT%MRS or LFAT%MRI in different ROIs  
  LFAT%MRI 
 
LFAT%MRS 
Mean     
(ROI 1-4) 
ROI 1 ROI 2 ROI 3 ROI 4 Left lobe Right lobe 
Body mass index 0.577*** 0.441*** 0.366***† 0.412*** 0.469*** 0.429*** 0.404*** 0.454*** 
Waist circumference 0.624*** 0.503*** 0.417***† 0.488*** 0.545*** 0.494*** 0.465*** 0.525*** 
Hip circumference 0.539*** 0.400*** 0.297**† 0.391*** 0.446*** 0.401*** 0.344***† 0.428*** 
Waist-to-hip–ratio 0.470*** 0.404*** 0.386*** 0.378*** 0.419*** 0.378*** 0.400*** 0.403*** 
Fasting plasma 
glucose 
0.467*** 0.352*** 0.269** 0.297** 0.383*** 0.404*** 0.298** 0.396*** 
HBA1c 0.445*** 0.477*** 0.424*** 0.464*** 0.482*** 0.491*** 0.449*** 0.493*** 
fS-insulin 0.615*** 0.518*** 0.468*** 0.450*** 0.512*** 0.537*** 0.477*** 0.534*** 
HOMA-IR 0.618*** 0.543*** 0.457*** 0.447***† 0.516*** 0.543*** 0.469*** 0.539*** 
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fS-triglyceride 0.547*** 0.431*** 0.387*** 0.384*** 0.429*** 0.422*** 0.406*** 0.427*** 
fS-HDL cholesterol -0.391*** -0.377*** -0.398*** -0.337*** -0.335*** -0.360*** -0.381*** -0.355*** 
S-AST 0.556*** 0.409*** 0.332***† 0.356***† 0.444*** 0.438*** 0.364***† 0.440*** 
S-ALT 0.708*** 0.574*** 0.504***†† 0.502***†† 0.594*** 0.604*** 0.527***† 0.604*** 
S-GGT 0.548*** 0.446*** 0.411*** 0.409*** 0.473*** 0.440*** 0.434*** 0.454*** 
Body fat (%) 0.348*** 0.249** 0.108† 0.221* 0.310** 0.286** 0.167 0.308** 
Intra-abdominal fat 0.668* ** 0.598*** 0.511***† 0.579*** 0.614*** 0.574**** 0.554*** 0.604*** 
Subcutaneous fat 0.521*** 0.427*** 0.295**† 0.406*** 0.485*** 0.453*** 0.343** 0.479*** 
Abbreviations: LFAT%MRS, % liver fat by proton magnetic resonance spectroscopy; LFAT%MRI, % liver fat by magnetic resonance 
imaging; ROI, region of interest; fS, fasting serum; HBA1c, glycosylated hemoglobin A1c; HDL, high density lipoprotein; S, serum; 
AST, aspartate aminotransferase; ALT alanine aminotransferase; GGT, gamma-glutamyltransferase. *p<0.05, **p<0.02, ***p<0.001 
for r-values; Hotelling-Williams test to compare r-values for the relationship between LFAT%MRS or LFAT%MRI in different ROIs and 
given metabolic parameters, †p<0.05, ††p<0.05 for LFAT%MRI in different ROIs vs. LFAT%MRS. 
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FIGURES 
Fig. 1. Positions of region of interests (ROIs) 1-4 in the liver and 3 ROIs in the 
spleen on T1-weighted dual-echo gradient-echo sequence. ROIs 3, 4 were in 
the right and ROIs 1, 2 in the left hepatic lobe. ROIs 1-4 belong to liver 
segment II, IV, VIII, VII, respectively. 
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Fig. 2. Correlation between% liver fat by proton magnetic resonance 
spectroscopy (LFAT%MRS) and liver fat fraction by magnetic resonance 
imaging (LFATFrMRI). LFATFrMRI in the right lobe was closely correlated with 
LFAT%MRS (r=0.837, p<0.001). 
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Fig. 3. % liver fat by magnetic resonance imaging (LFAT%MRI) in different 
region of interests (ROIs). Data are shown as mean ± SE. **p<0.02, 
***p<0.001. 
 
 
 
35 
 
Fig. 4. Receiver operating characteristic (ROC) curves to diagnose the 
non-alcoholic fatty liver disease using% liver fat by magnetic resonance 
imaging (LFAT%MRI) in the right and left lobe. Area under receiver operating 
characteristic (AUROC) was significantly higher using LFAT%MRI in the right 
(AUROC = 0.934±0.025,p< 0.001, sensitivity 86.5%, specificity 90.0%) rather 
than in the left (AUROC = 0.894±0.032,p<0.001, sensitivity 73.0%, specificity 
91.7%) lobe. 
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Fig. 5. The relationships between metabolic parameters andproton magnetic 
resonance spectroscopy (LFAT%MRS) or % liver fat by magnetic resonance 
imaging (LFAT%MRI) in different region of interests (ROIs). The 
Hotelling-Williams test was used to compare r-values for the relationship 
between LFAT%MRS(white bar) or LFAT%MRI in different ROIs (grey or black 
bars) and given metabolic parameters, *p<0.05, **p<0.02.FPG, fasting plasma 
glucose; HOMA-IR, Homeostasis model assessment-insulin resistance;BMI, 
body mass index; S-ALT, serum alanine aminotransferase. 
 
 
